Alan C. Moss

9.6k total citations · 1 hit paper
192 papers, 6.8k citations indexed

About

Alan C. Moss is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Alan C. Moss has authored 192 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Genetics, 89 papers in Epidemiology and 55 papers in Surgery. Recurrent topics in Alan C. Moss's work include Inflammatory Bowel Disease (91 papers), Microscopic Colitis (78 papers) and Eosinophilic Esophagitis (18 papers). Alan C. Moss is often cited by papers focused on Inflammatory Bowel Disease (91 papers), Microscopic Colitis (78 papers) and Eosinophilic Esophagitis (18 papers). Alan C. Moss collaborates with scholars based in United States, Ireland and Australia. Alan C. Moss's co-authors include Adam S. Cheifetz, Kavinderjit S. Nanda, Simon C. Robson, Garrett Lawlor, Eva Morris, Padraic MacMathúna, Maggie Ham, Francis A. Farraye, Joseph D. Feuerstein and J Leyden and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Alan C. Moss

189 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ulcerative Colitis

2019 301 citations Joseph D. Feuerstein, Alan C. Moss et al. profile →

Peers

Countries citing papers authored by Alan C. Moss

Since Specialization

Citations

This map shows the geographic impact of Alan C. Moss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan C. Moss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan C. Moss more than expected).

Fields of papers citing papers by Alan C. Moss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan C. Moss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan C. Moss. The network helps show where Alan C. Moss may publish in the future.

Co-authorship network of co-authors of Alan C. Moss

This figure shows the co-authorship network connecting the top 25 collaborators of Alan C. Moss. A scholar is included among the top collaborators of Alan C. Moss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan C. Moss. Alan C. Moss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Medical management of painful achalasia: a patient-driven systematic review 2024 ·Diseases of the Esophagus ·(unknown), (unknown), (unknown), Alan C. Moss, Majid Hashemi, Giovanni Zaninotto, Stefan Antonowicz	1
2	The Surface Morphology of Large Nonpedunculated Colonic Polyps Predicts Synchronous Large Lesions 2023 ·Clinical Gastroenterology and Hepatology ·(unknown), David J. Tate, Mayenaaz Sidhu, Sunil Gupta, (unknown), Karen Byth, Oliver Cronin, (unknown), (unknown), Rajvinder Singh, Gregor J. Brown, Spiro Raftopoulos, Luke F. Hourigan, Alan C. Moss, Amir Klein, Steven J. Heitman, Stephen J. Williams, Eric Lee, Nicholas G. Burgess, Michael J. Bourke	4
3	Optical Evaluation for Predicting Cancer in Large Nonpedunculated Colorectal Polyps Is Accurate for Flat Lesions 2021 ·Clinical Gastroenterology and Hepatology ·Sergei Vosko, Neal Shahidi, Mayenaaz Sidhu, W. Arnout van Hattem, Iddo Bar-Yishay, Scott Schoeman, David J. Tate, Luke F. Hourigan, Rajvinder Singh, Alan C. Moss, Karen Byth, Eric Y.T. Lee, Nicholas G. Burgess, Michael J. Bourke	20
4	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014 2018 ·Alimentary Pharmacology & Therapeutics ·Sarah Ballou, William Hirsch, Prashant Singh, Vikram Rangan, Judy Nee, Johanna Iturrino, Thomas Sommers, (unknown), Neil Sengupta, Andrea Bollom, Michael Jones, Alan C. Moss, Sarah N. Flier, Adam S. Cheifetz, Anthony Lembo	31
5	Endoscopic mucosal resection for large serrated lesions in comparison with adenomas: a prospective multicentre study of 2000 lesions 2016 ·Gut ·María Pellisé, Nicholas G. Burgess, Nicholas Tutticci, Luke F. Hourigan, Simon Zanati, Gregor J. Brown, Rajvinder Singh, Stephen J. Williams, Spiro Raftopoulos, Donald Ormonde, Alan C. Moss, Karen Byth, (unknown), Hema Mahajan, Duncan McLeod, Michael J. Bourke	91
6	Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages 2016 ·Inflammatory Bowel Diseases ·Shuji Mitsuhashi, Linda Feldbrügge, Eva Csizmadia, Masato Mitsuhashi, Simon C. Robson, Alan C. Moss	95
7	Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps 2015 ·Gut ·Nicholas G. Burgess, María Pellisé, Kavinderjit S. Nanda, Luke F. Hourigan, Simon Zanati, Gregor J. Brown, Rajvinder Singh, Stephen J. Williams, Spiro Raftopoulos, Donald Ormonde, Alan C. Moss, Karen Byth, (unknown), Duncan McLeod, Michael J. Bourke	65
8	A Fatal Case of Diffuse Enteritis After Colectomy for Ulcerative Colitis: A Case Report and Review of the Literature 2014 ·The American Journal of Gastroenterology ·Joseph D. Feuerstein, Sveta Shah, Robert M. Najarían, Deborah Nagle, Alan C. Moss	9
9	Characterization of Human CD39+ Th17 Cells with Suppressor Activity and Modulation in Inflammatory Bowel Disease 2014 ·PLoS ONE ·Maria Serena Longhi, Alan C. Moss, Aiping Bai, Yan Wu, Huang Huang, Adam S. Cheifetz, Francisco J. Quintana, Simon C. Robson	56
10	Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease 2014 ·Inflammatory Bowel Diseases ·Byron P. Vaughn, Manuel Martínez-Vazquez, Vilas Patwardhan, Alan C. Moss, William J. Sandborn, Adam S. Cheifetz	163
11	Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis 2014 ·Journal of Managed Care Pharmacy ·Jennifer Devlen, Kathleen Beusterien, Linnette Yen, Awais Ahmed, Adam S. Cheifetz, Alan C. Moss	26
12	Prevalence and Lifetime Risk of Endoscopy-related Complications Among Patients With Inflammatory Bowel Disease 2013 ·Clinical Gastroenterology and Hepatology ·(unknown), Mona Akbari, Laurie Gashin, Garret Cullen, Alan C. Moss, Daniel A. Leffler, Mark D. Aronson, Adam S. Cheifetz	17
13	Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis 2013 ·Cellular Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nestor Schor, Alan C. Moss	32
14	Nephrolithiasis in patients with inflammatory bowel disease in the community 2013 ·International Journal of Nephrology and Renovascular Disease ·(unknown), Alan C. Moss, Nestor Schor	48
15	Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine 2012 ·Clinical Pharmacology Advances and Applications ·Alan C. Moss, (unknown)	24
16	Abdominal phlegmons in Crohnʼs disease: Outcomes following antitumor necrosis factor therapy 2011 ·Inflammatory Bowel Diseases ·Garret Cullen, Byron P. Vaughn, Awais Ahmed, Mark A. Peppercorn, Martin P. Smith, Alan C. Moss, Adam S. Cheifetz	39
17	Melanin-concentrating hormone as a mediator of intestinal inflammation 2008 ·Proceedings of the National Academy of Sciences ·Efi Kokkotou, Alan C. Moss, Daniel Torres, Ιορδάνης Καραγιαννίδης, Adam S. Cheifetz, Sumei Liu, Michael J. O’Brien, Eleftheria Maratos–Flier, Charalabos Pothoulakis	50
18	SCG3 Transcript in Peripheral Blood Is a Prognostic Biomarker for REST-Deficient Small Cell Lung Cancer 2008 ·Clinical Cancer Research ·Alan C. Moss, Gregory M. Jacobson, Lauren Walker, Neil Blake, Ernie Marshall, Judy M. Coulson	47
19	The risks and the benefits of mesalazine as a treatment for ulcerative colitis 2007 ·Expert Opinion on Drug Safety ·Alan C. Moss, Mark A. Peppercorn	46
20	Corticotropin-Releasing Hormone Receptor 2-Deficient Mice Have Reduced Intestinal Inflammatory Responses 2006 ·The Journal of Immunology ·Efi Kokkotou, Daniel Torres, Alan C. Moss, Michael J. O’Brien, Dimitri E. Grigoriadis, Katia Karalis, Charalabos Pothoulakis	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact